TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial in Males With BPH (Enlarged Prostate)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
* Has been suffering for at least 6 months with any of the following symptoms:~* daytime or nighttime urinary frequency~* urgent feeling to urinate~* difficulty starting urinary stream~* interruption of urinary stream~* feeling of incomplete urination~* Has not had a previous episode of acute urinary retention~* Has not been diagnosed with prostate cancer~* Has not had previous prostate surgery~* Is not an insulin-dependent diabetic

- Gender: MALE
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Relapse Prevention Through Social Networking Groups

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Smoked at least 1 cigarette a day when first joined ICSC~* Aged 18 or above at the baseline of the RCT~* Clients who have received 3 to 5 smoking cessation counseling provided by ICSC~* Reported tobacco abstinence in the past 7 days at the 8-week follow-up since receiving treatment from ICSC~* Able to communicate in Cantonese and read Chinese~* Have a local network mobile phone with mobile internet access~Exclusion Criteria:~* Those with unstable physical or psychological conditions as advised by the doctor or counselor in charge~* Smokers with diagnosed alcohol dependence by clinicians or the score of the Alcohol Use Disorders Identification Test (AUDIT) is 8 or higher

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- WhatsApp (Type: EXPERIMENTAL): Provide peer support and deliver relapse prevention messages through WhatsApp for 8 weeks and telephone follow ups
- Facebook (Type: EXPERIMENTAL): Provide peer support and deliver relapse prevention messages through Facebook for 8 weeks and telephone follow ups
- Control (Type: NO_INTERVENTION): Telephone follow ups and received a self-help book only

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Galantamine Effects on Cognitive Function in Abstinent Cocaine Users

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and females, between the ages 21 and 50~* Fulfill criteria for past cocaine dependence~* No cocaine use for the past 30 days~* No other current dependence or abuse of other drugs or alcohol~* No current medical problems and normal ECG~* Not pregnant,nor breast feeding,~* Using acceptable birth control methods.~Exclusion Criteria:~* Current major psychiatric illness including mood, psychotic or anxiety disorders~* History of major medical illnesses; including asthma or chronic obstructive lung disease, history or current gastrointestinal ulcer, hepatic or renal impairment and cardiac rhythm disturbances~* Use of other medications including,drugs that slow heart rate~* Known allergy to galantamine

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Galantamine 8 mg/day (Type: ACTIVE_COMPARATOR): Galantamine 8 mg/day
- Placebo (Type: PLACEBO_COMPARATOR): placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Use of Anti-oxidants to Reduce Sequela of Mild Traumatic Brain Injury (mTBI) After Blast Exposure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Be active duty United States Service member~2. Be between the ages of 18 and 50 years~3. Present to TQ Surgical within 24 hours of blast exposure.~4. Have complains consistent with possible TBI including hearing loss, dizziness, lightheadedness, cognitive difficulties, and/or had loss of consciousness.~5. Are not expressly excluded by the criteria listed below.~Exclusion Criteria:~1. Require urgent or emergent surgical procedures.~2. Will require medical evacuation to any level III or higher facility (other then to a level III for a CT scan only).~3. Has evidence of an open head wound.~4. Pregnant Females~5. The use, within the last seven days, of a nutritional supplement containing an anti-oxidant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- 2 (Type: PLACEBO_COMPARATOR): control
- 1 (Type: EXPERIMENTAL): Active medicine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, within age limits as defined by local regulations and local product label, who have previously been treated with, who are currently being treated with or initiating treatment with ranibizumab for any approved indication included in the local product label~* Willing and able to provide informed written consent personally or by legal proxy~Exclusion Criteria:~* Simultaneous participation in a study that includes administration of any investigational drug or procedure~* Systemic or ocular treatment with any VEGF inhibitor other than ranibizumab in the 90 days prior to enrollment~* Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ranibizumab (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* 18 to 50 years of age at the time of enrollment.~* Signed the informed consent document.~* Subject judged to be healthy by a qualified physician~Exclusion Criteria:~* Abnormal physical findings of clinical significance at the screening examination~* Significant abnormal laboratory values at the Screening Visit.~* Clinically significant symptoms or conditions that may have placed the subject at an unacceptable risk as a participant in the trial, or that may have interfered with the absorption, distribution, metabolism or excretion of the IMP.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- STS101 1.5 mg (Type: EXPERIMENTAL): STS101 (dihydroergotamine nasal powder), 1.5 mg
- STS101 3.0 mg (Type: EXPERIMENTAL): STS101 (dihydroergotamine nasal powder), 3.0 mg
- STS101 6.0 mg (Type: EXPERIMENTAL): STS101 (dihydroergotamine nasal powder), 6.0 mg
- DHE intramuscular injection (Type: ACTIVE_COMPARATOR): Dihydroergotamine mesylate
- DHE nasal spray (Type: ACTIVE_COMPARATOR): Dihydroergotamine mesylate

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of a Web-based Sexual Violence Risk Reduction Program for Female College Students

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* female, aged 18-20 years, full-time freshmen, matriculated at Georgia State University, Emory University, or University of Georgia, and single (i.e., not in a committed dating relationship).~Exclusion Criteria:~* other education levels, married, and/or graduate status

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 20 Years
- Healthy Volunteers: t

Study Arms:
- RealConsent (Type: EXPERIMENTAL): A 3-hour web-based program designed to teach female college freshmen strategies to reduce their risk of sexual violence victimization.
- Stress and Mood Management (Type: PLACEBO_COMPARATOR): A 3-hour general mental health web-based program.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Observational Study to Describe Characteristics and Management of Patients Treated With Denosumab (Prolia®) in Routine Clinical Practice

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~* Women with a clinical diagnosis of postmenopausal osteoporosis~* Decision has been made to treat with denosumab 60 mg once every 6 months~* Have received their first injection of denosumab within 8 weeks prior to enrolling in this study.~* Appropriate written informed consent has been obtained (as required per local country regulations)~Exclusion Criteria~* Participating in ongoing or have participated in previous denosumab clinical trials~* Participation in other clinical or device trials in the last 6 months~* Contra-indicated for treatment with Prolia® according to the approved applicable local product label.~* Subject has any kind of disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Denosumab (Type: None): Patients with postmenopausal osteoporosis (PMO) who received at least 1 injection of denosumab 60 mg subcutaneously in the Czech Republic and Slovakia.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BE Study of Two Formulations of Rivaroxaban 2.5 mg in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male/female aged 19 to 55 with body mass index(BMI) between 18.5 and 30kg/m2~* Acceptable medical history, physical examination, laboratory tests and EKG, during screening~* Subjects who has signed a written informed consent voluntarily~Exclusion Criteria:~* History of clinically significant medical history or current disease~* Hypotension (SBP ≤ 90 mmHg or DBP ≤ 60 mmHg) or hypertension (SBP~  ≥ 140 mmHg or DBP ≥ 90 mmHg).~* AST(SGOT) or/and ALT(SGPT) \> 1.5 times of normal upper limit~* Total bilirubin \> 2.0 mg/dl~* Volunteers considered not eligible for the clinical trial by the investigator~* Administration of other investigational products within 6 month prior to the first dosing.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Group1 (Type: EXPERIMENTAL): 17 subjects, Cross-over, Single dose of comparator on day1, YHP1807 on day8
- Group2 (Type: ACTIVE_COMPARATOR): 17 subjects, Cross-over, Single dose of YHP1807 on day1, comparator on day8

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Alzheimer's type dementia, rated as severe~* progressive worsening of memory and other cognitive functions~* brain imaging (CTor MRI scan) within last 3 years~* ability to be mobile (aided or unaided) with sufficient vision and hearing to comply with testing.~Exclusion Criteria:~* Dementia caused by cerebrovascular disease~* disturbances of consciousness, delirium, psychosis~* severe aphasia~* or major sensorimotor impairment~* cognitive impairment due to acute cerebral trauma, hypoxic cerebral damage, vitamin deficiency, infections, primary of metastatic cerebral neoplasia, endocrine or metabolic disease or mental retardation, pregnant or nursing women or those without adequate contraception.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intravenous Pentamidine for Pneumocystis Jirovecii Pneumonia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adults (18 years or older)~* Hematologic malignancy diagnosis or stem-cell transplant recipient~* Eligible for PJP prophylaxis therapy at time of enrollment as per institutional guidelines in compliance with NCCN guidelines. These patients include:~* Acute myeloid leukemia patients receiving induction and consolidation (first line and relapsed/refractory)~* Acute lymphoid leukemia patients receiving HyperCVAD/R (cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine, rituximab)~* Lymphoma patients receiving ICE (ifosfamide, carboplatin, etoposide), DA-R-EPOCH (dose-adjusted rituximab, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin), and other inpatient lymphoma regimens~* Patients receiving other inpatient chemotherapy regimens that are given on a monthly basis~* Patients who have received an allogeneic stem cell transplant~* Have given informed consent~* May have previously received inhaled or IV pentamidine~Exclusion Criteria:~* Pregnancy~* Prisoners~* Patients with a documented allergy or hypersensitivity to pentamidine.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IV pentamidine (Type: None): Pentamidine 4mg/kg IV every month (maximum 300mg)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Paricalcitol and Endothelial Function in Chronic Kidney Disease Patients (the PENNY Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with iPTH level \> 65 pg/ml; Ca between 8.4- 10.00 mg/dL and P between 2.9-4.5~* Negative serum pregnancy test for female subjects of childbering potential.~* Informed consent.~Exclusion Criteria:~* Use vitamin D supplements.~* Altered liver function tests (bilirubin, aminotransferases and total alkaline phosphatase \> 3 times the upper limit of normal ranges).~* Sympthomatic cardiovascular disease on the basis of clinical history. Cancer.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo capsules daily for 12 weeks.
- Paracalcitol (Type: EXPERIMENTAL): see Intervention description for details.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Levetiracetam Treatment of Tardive Dyskinesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: meet Glazer Morgenstern criteria for TD -~Exclusion Criteria: none~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Levetiracetram Administration (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Couple-Based PTSD Treatment and Couple-Based PTSD Education

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Exposure to at least one combat-related stressful event during combat deployment,~* Current diagnostic criteria for PTSD for that event, and~* Veteran is in a committed relationship and living with an opposite sex partner for at least six months.~Exclusion Criteria:~* Current psychotic symptoms in either partner,~* Current diagnosis of alcohol or drug dependence in either partner,~* History of recent physical assault/abuse,~* Currently receiving an evidence-based PTSD treatment (exposure-based or cognitive processing therapy)~* Currently receiving couples therapy or family therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Structured Approach Therapy (Type: EXPERIMENTAL): Couple-Based Intervention called Structured Approach Therapy provides skills training to couple so they can reduce PTSD.
- PTSD Family Education (Type: ACTIVE_COMPARATOR): Couple-Based Education called PTSD Family Education teaches couple about PTSD symptoms, related problems, and treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* male or female, 18 years or older~* blood culture positive for S. aureus~* at least one sign or symptom attributable to S. aureus bacteremia~* known or suspected complicated S. aureus BSI and/or endocarditis by Modified Duke Criteria~* patient is not pregnant or breastfeeding and is not of reproductive potential or agrees to use contraception if of reproductive potential.~Exclusion Criteria:~* patient previously received CF-301.~* treatment with any potentially effective (anti-staphylococcal) systemic antibiotic for more than 72 hours within 7 days before randomization.~* presence of any removable infection source that will not be removed or debrided within 72 hours after randomization.~* brain abscess or meningitis.~* community acquired pneumonia or known polymicrobial bacteremia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CF-301 (Type: EXPERIMENTAL): Patients will receive a single IV infusion of CF-301 in addition to standard of care (SOC) antibacterial therapy selected by the investigator.
- Placebo (Type: PLACEBO_COMPARATOR): Patients will receive a single IV infusion of placebo in addition to standard of care (SOC) antibacterial therapy selected by the investigator.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria~1. Male or female adults 65 years of age or greater.~2. Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.~3. Female subject of nonchildbearing potential; male subject not able to father children or who is able to father children and willing to use a highly effective method of contraception.~4. Male or female adults who meet 1 of the following:~   1. Vaccination with PPSV23 greater than or equal to 1 year and less than or equal to 5 years prior to vaccination in the study, and no prior 13vPnC vaccination (Cohort A).~  2. Vaccination with 13vPnC greater than or equal to 6 months prior to vaccination in the study, and no prior PPSV23 vaccination (Cohort B).~  3. Vaccination with 13vPnC followed by PPSV23 (PPSV23 vaccination greater than or equal to 1 year prior to vaccination in the study) (Cohort C).~Exclusion Criteria~1. Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.~2. History of microbiologically proven invasive disease caused by S pneumoniae.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 13vPnC (Type: ACTIVE_COMPARATOR): Pneumococcal conjugate vaccine
- PPSV23 (Type: ACTIVE_COMPARATOR): Pneumococcal polysaccharide vaccine
- 20vPnC (Type: EXPERIMENTAL): Pneumococcal conjugate vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete